Introduction {#sec1}
============

*Actinobaculum schaalii* is a Gram-positive bacillus that was described for the first time in 1997 [@bib1]. Other species described in the same genus include *Actinobaculum suis, Actinobaculum urinale* and *Actinobaculum massiliense. A. suis* has been reported as a veterinary pathogen [@bib2], [@bib3]. *A. urinale* is rarely found in human infections but has been coisolated with *A. schaalii* [@bib4]. Recent changes in the classification were made, reclassifying *A. schaalii* as *Actinotignum schaalii* [@bib5]. It is a nonsporulated bacillus. Its morphology is nonspecific, and it sometimes looks like immobile corynebacteria. It is facultative anaerobic, which implies a possible anaerobic culture and culture in atmosphere supplemented with 5% CO~2~. Its aerobic culture is tedious and is facilitated by the use of blood-enriched media. These characteristics explain the difficulty of isolation, especially from urine, which is routinely incubated aerobically on unsupplemented media, such as chromogenic ones. *A. schaalii* is described as a commensal of the urogenital tract also found on the skin [@bib6]. Many cases of infections have been reported, and urinary tract infections (UTIs) seem to predominate, particularly among elderly patients [@bib7], [@bib8]. However, other types of infections exist. Since its discovery, the number of reported isolates and clinical cases is increasing. It is thus considered to be an emerging pathogen.

The aim of our study was to assess retrospectively the frequency and circumstances of isolation of *A. schaalii* over 10 years in CH Versailles (France) and the role of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) in the identification of this bacterium.

Materials and Methods {#sec2}
=====================

Using SIRScan software (I2A), we extracted all *A. schaalii* strains between July 2004 and February 2015. Strains were identified by sequencing of the 16S ribosomal DNA from colonies using the primers A2 (5′-AGAGTTTGATCATGGCTCAG-3′) and S15 (5′-GGGCGGTGTGTACAAGGCC-3′) [@bib9] until November 2011. From December 2011, MALDI-TOF (Microflex; Bruker Daltonics, Wissembourg, France) was used (databases DB 4613 and 5627). Retrospective mass spectrometry (MS) identification was carried out for stored isolates initially identified by sequencing.

For urine samples, microscopic examination (Gram coloration) was carried out in case of leukocyturia \>10^4^ leucocytes/mL. Ten microlitres was routinely seeded onto a chromogenic agar incubated aerobically. If microscopic examination showed only Gram-positive bacilli, blood agar was also seeded under atmosphere enriched in CO~2~ for 48 hours.

Clinical observations of all cases were reviewed to determine the pathogenic role of the isolate. The following informations were collected: age, sex, infection risk factors, site and isolation circumstances. We considered that *A. schaalii* was a pathogen when it was clearly mentioned in the actual benefit account and/or when it was the only bacteria isolated from the infectious site.

Results {#sec3}
=======

Between July 2004 and February 2015, a total of 24 *A. schaalii* isolates were collected from 24 patients. Six isolates were initially identified by sequencing, and the other 18 were identified by MALDI-TOF. Among the six isolates initially identified by sequencing, three were further confirmed by MS. The results of the different scores obtained are shown in [Table 1](#tbl1){ref-type="table"}. For isolates identified by MS, the statistical averages of the scores obtained for each of the first three proposed identifications are shown in [Fig. 1](#fig1){ref-type="fig"}.

The circumstances of isolation and the clinical characteristics of the patients are summarized in [Table 2](#tbl2){ref-type="table"}. Strains were predominantly isolated from abscesses and collections (58% of cases, 14 isolates): bone infections and soft tissue infections including cysts and abscesses (wall, pilonidal sinus, breast, ankle *etc.*). The urine samples corresponded to 33% of the isolates: eight cases, including seven cases after November 2011 ([Table 3](#tbl3){ref-type="table"}). Finally, blood cultures represented two isolates. Urine and blood cultures were monomicrobial, while 64% (9/14) abscesses and collections were plurimicrobial.

The male/female sex ratio of the 24 patients was 1.2 with a mean age of 58.2 years (range, 8--96 years). In 75% of cases, at least one risk factor for infection was present, including age \>65 years, immunosuppression, abnormality of the genitourinary tract and diabetes.

Discussion {#sec4}
==========

Introduction of MALDI-TOF in clinical practice has led to an increase in the frequency of *A. schaalii* isolates in our laboratory ([Table 3](#tbl3){ref-type="table"}). Indeed, between July 2004 and November 2011, six strains of *A. schaalii* were identified by sequencing, vs. 18 isolates by MS since November 2011. The most likely explanation is that before November 2011, routine bacterial identification was performed by biochemical tests such as API strips (bioMérieux, Marcy l\'Etoile, France) or Vitek cards (bioMérieux). These techniques did not permit the identification of *A. schaalii* because this organism was then not included in the database [@bib10]; the latest 2015 version of the map Vitek anaerobe and Corynebacterium (ANC) now allows its detection.

Analysis of the results of identification by MS ([Fig. 1](#fig1){ref-type="fig"}) revealed that the first three proposals correspond to the three spectra of *A. schaalii* of Bruker base ([Table 4](#tbl4){ref-type="table"}) in 17 of 18 cases, with a median identification score of 2.045 (1.82 to 2.26) for the first proposal. The three other *Actinobaculum* species in the database are never proposed. In addition, retrospective MS performed on three isolates stored and previously identified by 16S ribosomal DNA sequencing was successful for identification. As previously described [@bib10], we confirmed the identification performance by Microflex MALDI-TOF (Bruker) for *A. schaalii* with the three strains also identified by sequencing. However, it was reported that the MALDI-TOF Vitek (bioMérieux) does not currently allow the identification of *A. schaalii* [@bib11], [@bib12].

The pathogenic role of *A. schaalii* was not accepted by clinicians in two cases of bacteraemia because another recognized pathogen was isolated from blood cultures for each of the two patients. In addition, the presence of this microorganism as a contaminant of blood cultures suggests a possible presence on the skin [@bib6]. Nevertheless, we cannot exclude its participation in the infection.

Urine samples all exhibited significant leukocyturia (\>10^4^/mL), a positive direct microscopic examination with Gram-positive bacilli and monomicrobial culture \>10^5^ CFU/mL. The isolation in urine requires seeding on a blood agar in atmosphere enriched in CO~2~. This is routinely carried out in our laboratory on urine samples with leukocyturia (\>10^4^/mL) and Gram-positive bacilli on microscopic examination. The collected clinical data are consistent with a diagnosis of infection of the urogenital tract. *A. schaalii* is thus responsible for UTI in eight cases. One or more risk factors were found in these patients, highlighting the opportunistic nature of the microorganism. Advanced age is one of those risk factors (seven of eight patients were aged \>65 years) with urinary infection of *A. schaalii.* However, infections in young subjects should not be excluded [@bib13], as evidenced by case of acute pyelonephritis in a 8-year-old patient.

To assess the clinical relevance of *A. schaalii*, its isolation in urine samples must be associated with symptoms of UTI because it is important to remember that it can sometimes be a urinary commensalism. As such, a prospective Danish study showed that *A. schaalii* could be detected by PCR in urine in more than 22% of patients aged \>60 years, despite the absence of clinical signs in certain cases [@bib14]. This may explain why *A. schaalii* is often reported to exist within polymicrobial urine [@bib15]. In our practice, when there is a dominant uropathogen, the other possibly associated bacteria are not always identified, as they are considered commensal.

For abscesses and collections, we distinguish between mono- and plurimicrobial samples. Accountability is questionable for samples with various microorganisms. It is easier when there are no other related bacteria. This is the case of a 34-year-old patient with recurrent breast abscess, in which *A. schaalii* was clearly implicated, as specified in the medical report. As in most of the cases we have described, the patients were treated by surgery only without antibiotics, and the outcome was always good, suggesting that, unlike UTIs, antibiotic treatment is not routinely required to treat the infection. We emphasize that compared to urinary isolates, the age of the patient is more important for abscesses and collection. Another difference concerns young patients without risk factors, including an abdominal wall abscess in a 23-year-old patient, a pilonidal sinus abscess in a 20-year-old man and breast abscesses observed in a 34-year-old patient. However, it was suggested that *A. schaalii* could contribute to the infectious process even when it is isolated in the presence of other bacteria [@bib15]. Cases of endocarditis [@bib16], Fournier gangrene [@bib17], spondylitis [@bib18] and urosepsis [@bib19] have already been reported, underscoring the invasive potential of this microorganism.

Overall, although UTIs are the most frequently reported in the literature [@bib12], our study shows that the isolation of *A. schaalii* in abscesses and collections is common. The frequency of isolation has increased since the onset of use of MS in our laboratory. This suggests that the emerging nature of infections due to *A. schaalii* is probably attributable to gaps in methods for identifying in the daily microbiology before the era of MS.

To conclude, our study emphasizes the role of MALDI-TOF in the accurate identification of *A. schaalii.* This process, which is less-time consuming and less expensive than molecular biology, advantageously replaces biochemical tests in the identification of this organism. The emergence of this bacterium presumably is the result, at least in part, of an evolution in identification methods. This will permit a better understanding of the epidemiology of *A. schaalii.* The pathogenic role of *A. schaalii* is questionable in some cases. Further studies are therefore needed, especially on the cutaneous habitat and virulence of this bacterium, to better interpret its presence in a clinical sample.
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###### 

Retrospective mass spectrometry identification of three *Actinobaculum schaalii* isolates[a](#tbl1fna){ref-type="table-fn"}

  Isolate no.   Identification (score):                          
  ------------- ------------------------- ---------------------- ----------------------
  1             *A. schaalii* (2.03)      *A. schaalii* (2)      *A. schaalii* (1.8)
  2             *A. schaalii* (2.15)      *A. schaalii* (1.75)   *A. schaalii* (1.63)
  3             *A. schaalii* (1.93)      *A. schaalii* (1.57)   *A. schaalii* (1.54)

Isolates were initially identified by sequencing.

###### 

Clinical characteristics of patients

  Patient no.   Age/sex   Risk factor                     Nature of sampling   Other microorganism(s)                                                 Accountability *Actinobaculum schaalii*   Diagnosis retained
  ------------- --------- ------------------------------- -------------------- ---------------------------------------------------------------------- ----------------------------------------- --------------------------------------------------
  1             58/F      Cancer                          Blood culture        No                                                                     No                                        *Staphylococcus epidermidis* portacath infection
  2             55/M      Monoclonal gammopathy           Blood culture        No                                                                     No                                        *Enterobacter cloacae* sepsis
  3             8/M       Undescended testis, enuresis    Urine                No                                                                     Yes                                       UTI
  4             81/M      Age, squamous cell carcinoma    Urine                No                                                                     Yes                                       UTI
  5             83/F      Age, diabetes                   Urine                No                                                                     Yes                                       UTI
  6             83/F      Age, colectomy, villous tumor   Urine                No                                                                     Yes                                       UTI
  7             96/F      Age, urinofaecal incontinence   Urine                No                                                                     Yes                                       UTI
  8             75/F      Age                             Urine                No                                                                     Yes                                       UTI
  9             80/M      Age                             Urine                No                                                                     Yes                                       UTI
  10            66/M      Age                             Urine                No                                                                     Yes                                       UTI
  11            77/M      Age, diabetes                   Collection           No                                                                     Yes                                       Osteoarthritis
  12            23/M      None                            Collection           No                                                                     Yes                                       Abdominal wall abscess
  13            69/M      Age                             Collection           No                                                                     Yes                                       Secondarily infected sebaceous cyst
  14            20/F      None                            Collection           No                                                                     Yes                                       Pilonidal sinus abscess
  15            34/F      None                            Collection           No                                                                     Yes                                       Breast abscess
  16            17/M      None                            Collection           *Peptostreptococcus* spp.                                              No                                        Malleolus abscess
  17            28/M      None                            Collection           *Proteus mirabilis, Klebsiella pneumoniae, Enterococcus faecalis*      No                                        Collection of left tibia
  18            56/M      Diabetes                        Collection           *Streptococcus* spp., *Peptostreptococcus* spp.                        No                                        Secondarily infected sebaceous cyst
  19            74/F      Age                             Collection           *Actinomyces* spp., *Peptoniphilus* spp.                               No                                        Lipoma secondarily infected
  20            69/M      Age, diabetes                   Collection           *Finegoldia* spp., *Anaerococcus* spp.                                 No                                        Diabetic foot ulcer
  21            54/F      Diabetes                        Collection           *Acinetobacter* spp., *Helcococcus* spp., *Anaerococcus* spp.          No                                        Abscess on sternotomy
  22            77/M      Age                             Collection           *P. mirabilis, Morganella morganii*                                    No                                        Ankle osteitis
  23            27/F      None                            Collection           *Actinomyces turicensis*                                               No                                        Vaginal abscess
  24            88/F      Age                             Collection           *Staphylococcus aureus, Fascioloides magna, Propionibacterium acnes*   No                                        Shoulder fistula

UTI, urinary tract infection.

###### 

Sites of isolation of *A. schaalii* before and after introduction of MS

  Introduction of MS   Urine   Abscess/collection   Blood culture   Total
  -------------------- ------- -------------------- --------------- -------
  Before               1       5                    0               6
  After                7       9                    2               18

MS, mass spectrometry.

###### 

Mass spectrometer (Bruker Daltonics) local database for *Actinobaculum* spp.

  Species                    Database entry
  -------------------------- ---------------------
  *Actinobaculum schaalii*   70710715001 MVC
  *A. schaalii*              DSM 15541T DSM
  *A. schaalii*              RV_BA1_032010_E LBK
  *Actinobaculum suis*       DSM 20639T DSM
  *A. suis*                  GD75 GDD
  *Actinobaculum urinale*    DSM 15805T DSM
